Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody

Published: Tuesday, July 22, 2014
Last Updated: Tuesday, July 22, 2014
Bookmark and Share
Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases.

MRC Technology has announced that it has successfully humanized an anti-tau monoclonal antibody, which has applications in the treatment of Alzheimer’s and related neurodegenerative tauopathies.

The humanized tau antibody represents an important milestone for developing a disease modifying immunotherapy for Alzheimer’s disease. MRC Technology was contracted to humanize the antibody by AXON Neuroscience SE, a biotechnology company dedicated to the development of disease modifying immunotherapeutics and early diagnostics for Alzheimer's disease.

Alzheimer’s disease is characterized by the presence of neurofibrillary tangles consisting of diseased forms of protein tau. Tau cortical neurofibrillary tangles correlate well with the severity of cognitive impairment in Alzheimer’s disease and thus represent a valuable target for disease modifying therapy. Targeting disease modified tau appears to be a promising way to slow down or even stop progression of the disease.

Michael Dalrymple, Director of Business Development at MRC Technology, said: “We are very pleased with the outcome of this project and are hopeful that the positive evaluation results for the humanized antibody will prove to be a milestone in the development of effective treatments for this debilitating disease.”

“Treatment of Alzheimer’s disease is still recognized as an unmet medical need. Our company has considerable expertise in the area and I believe we are on the right track to developing an effective therapy that has the potential to stop progress of the disease,” commented Roman Sivak, Chief Executive Officer at AXON Neuroscience. “We thank MRC Technology for their invaluable support in humanizing this antibody, an essential step in its development as an immune-based therapeutic.”

MRC Technology has humanized over 50 antibodies to date, including three marketed products, Tysabri (natalizumab), Actemra (tocilizumab) and Entyvio (vedolizumab). A further six are in clinical trials (including pembrolizumab (MK3475)), with two more in preclinical studies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology and DEBRA Austria Sign Agreement
MRC Technology, a medical research charity, has signed an agreement to review DEBRA Austria’s research portfolio, aiming to identify promising projects and results which could be suitable for translation into better treatments.
Wednesday, April 27, 2016
MRC Technology Completes Move to Stevenage Open Innovation Campus
Relocation forms part of strategy to foster new collaborative partnerships.
Wednesday, April 20, 2016
MRC Technology and IPS-CAS Collaborate
Company has announced collaboration with Institut Pasteur of Shanghai, Chinese Academy of Sciences to develop new therapeutic antibodies.
Thursday, April 07, 2016
MRC Technology Appoints Two New Members to Board of Trustees
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.
Thursday, April 07, 2016
Charity Seeks Diagnostic Partners to Deliver New Patient Treatments
Call for Diagnostics from MRCT for scientists with promising results lead to new tests.
Thursday, October 29, 2015
MRC Technology Appoints Technology Transfer Director
Appointment of Andrew Farquharson as Director from 1 September.
Wednesday, July 08, 2015
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
MRC Technology Appoints Finance Director
MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014.
Friday, April 17, 2015
MRC Technology Negotiates Licence Deal with Quantifoil Micro Tools GmbH for Ultrastable Gold Support (UltrAuFoil) Technology
The gold supports enable the determination of currently intractable protein structures by electron cryomicroscopy.
Tuesday, March 31, 2015
First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
MRC Technology Appoints General Counsel and Company Secretary
Dr Edward Bliss will join MRCT on 16 March.
Wednesday, February 04, 2015
MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership
Partnership in China to develop novel therapeutics for Parkinson’s disease.
Friday, November 28, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!